| March 11-13, 2022 Hyatt Regency Coconut Point | Naples, FL |
Download & Print Agenda |
| Course Directors: Tolga Erim, DO & Joel E. Richter, MD, MACG |
|
| Friday, March 11, 2022 │ All times are listed in the Eastern Time Zone | |
|---|---|
| 7:00 am | Registration / Continental Breakfast in the Exhibit Hall |
| 7:50 am | Welcome and Introductions Tolga Erim, DO |
| SESSION 1: Upper GI |
|
| 8:00 am | Unusual Esophagitises You Will See in Practice John W. Jacobs, Jr., MD Identify the latest concepts and treatments for patients with unusual esophagitis. |
| 8:20 am | Applications of POEM in UGI Diseases Tolga Erim, DO Discuss the current state of technology with applications in upper GI disease detection and identification, how it may impact daily practice, and potential issues. |
| 8:40 am | Gastroparesis Treatment, What Works? Baharak Moshiree, MD, MS-CI, FACG Highlight the advancements in the diagnosis and treatment of gastroparesis. |
| 9:00 am | Bariatric Endoscopy—Bridging the Medical-Surgical Gap for Obesity Management Ali Abbas, MD Describe when to recommend endoscopic versus surgical treatments of obesity and describe available options with pros and cons of each approach. |
| 9:20 am | Case Presentation |
| 9:30 am | Panel Discussion / Q&A |
| 10:00 am | Break / Visit Exhibits |
| SESSION 2: IBD |
|
| 10:30 am | Approach to Mild-Moderate IBD—Drugs to Alternative Medicine Jennifer L. Seminerio, MD Discuss how to apply current treatment guidelines on positioning IBD therapies in clinical practice and interpret the evidence base for popular alternative therapies including medical marijuana, herbal remedies, and probiotics. |
| 10:50 am | Severe Hospitalized Patient With IBD Asad Ur Rahman, MD Describe the management and treatment considerations for hospitalized patients with severe UC and Crohn’s. |
| 11:10 am | Update on Malignancies in IBD Jana G. Al Hashash, MD, MSc, FACG Summarize primary and secondary cancer prevention in IBD patients, including the use of chromoendoscopy. |
| 11:30 am | Choosing Precision Therapy for IBD Anita Afzali, MD, MPH, FACG Analyze the available data and positioning in IBD management of patient-centered goals and published algorithms of care. |
| 11:50 am | Case Presentation |
| 12:00 noon | Panel Discussion / Q&A |
| 12:30 pm | Daily Wrap-up |
| 12:40 pm | Adjourn for the Day |
| Saturday, March 12, 2022 | |
| 7:30 am | Continental Breakfast in the Exhibit Hall |
| 7:55 am | Morning Announcements Tolga Erim, DO |
| SESSION 3: Pancreas |
|
| 8:00 am | Incidental Pancreas Lesions Laith H. Jamil, MD, FACG Explain the management and treatment of pancreatic lesions. |
| 8:20 am | Does My Patient Have Exocrine Pancreas Insufficiency? Jose M. Nieto, DO, FACG Identify the etiologies of exocrine pancreatic insufficiency (EPI), recognize the symptoms of EPI, and understand the impact and consequences of untreated EPI. |
| 8:40 am | Recurrent Acute Pancreatitis: Causes and Management Andres Gelrud, MD, MMSc Review the ACG guidelines and identify the management and treatments for recurrent acute pancreatitis. |
| 9:00 am | Management of Patients at High Risk for Pancreatic Cancer Eileen So Carpenter, MD, PhD Outline and describe how to assess the management of patients at high risk for pancreatic cancer with a focus on the most commonly encountered scenarios. |
| 9:20 am | Case Presentation |
| 9:30 am | Panel Discussion / Q&A |
| 10:00 am | Break / Visit Exhibits |
| SESSION 4: Liver |
|
| 10:30 am | Management of Hepatocellular Carcinoma Patricia D. Jones, MD, MSCR Review the risk factors associated with Hepatocellular Carcinoma (HCC), as well as diagnostic testing, recognition, and management of liver disease in patients with HCC. |
| 10:50 am | Liver Alphabet Soup: PBC, PSC, AIH, etc. Mitchell L. Shiffman, MD, FACG Identify the causes, diagnostic evaluation, and the natural history and treatment of primary biliary cirrhosis, primary sclerosing cholangitis, and other hepatic disorders. |
| 11:10 am | Management of End Stage Liver Disease Nancy S. Reau, MD, FACG Review important issues regarding assessment and treatment options for patients with end stage liver disease. |
| 11:30 am | Update in Liver Transplantation Raymond Lee, MD Recognize how to evaluate patients for and treat patients who have had liver transplantation and how to recognize when patients should be transferred to a liver transplant center. |
| 11:50 am | Case Presentation |
| 12:00 noon | Panel Discussion / Q&A |
| 12:30 pm | Daily Wrap-Up |
| 12:40 pm | Adjourn for the Day |
| Sunday, March 13, 2022 | |
| 7:30 am | Continental Breakfast in the Exhibit Hall |
| 7:55 am | Morning Announcements Tolga Erim, DO |
| SESSION 5: Lower GI and Colon Cancer |
|
| 8:00 am | When Should Screening Start and Stop? Update on ACG CRC Guidelines Jodie A. Barkin, MD Identify the evidence for colon cancer screening in average risk and those with family history of CRC. |
| 8:20 am | EMR of Large Colorectal Lesions, Hot or Cold? Bashar J. Qumseya, MD, MPH Discuss current state of technology with applications in large colorectal lesions and identification, how this may impact daily practice, and potential issues. |
| 8:40 am | Hereditary Colon Cancer Management in Everyday Practice Brenda G. Jimenez, MD Recognize the role of hereditary syndromes in the pathway to colorectal cancer and generate surveillance strategies for your patients with these syndromes. |
| 9:00 am | Anorectal Motility Disorders Diagnosis and Management James C. Reynolds, MD, FACG Explain innovative approaches for the diagnosis and management of anorectal motility disorders. |
| 9:20 am | Case Presentation |
| 9:30 am | Panel Discussion / Q&A |
| 10:00 am | Break / Visit Exhibits |
| SESSION 6: How I Do It |
|
| 10:30 am | Making Sense of IBD Guidelines for Everyday Practice Maria T. Abreu, MD Describe how to choose IBD therapies based on prognosis and confirm effectiveness and identify targets of treatment that are individualized based on patient symptoms and objective measures of disease activity. |
| 10:50 am | Non-Pharmacological Therapies for IBS Brooks D. Cash, MD, FACG Recognize the evidence supporting exercise, diet, and CAM therapies for IBS. |
| 11:10 am | Refractory Barrett’s Esophagus Douglas K. Pleskow, MD, FACG Identify the risk factors associated with development of esophageal adenocarcinoma, determine surveillance protocols and intervals after being diagnosed with Barrett’s esophagus, and assess the role of endoscopic therapy for patients with refractory Barrett’s esophagus. |
| 11:30 am | Chicago 4: How It May Be Changing My Esophageal Motility Practice John E. Pandolfino, MD, MSCI, FACG Develop a more refined appreciation of motility disorders beyond a simple decision tree algorithm. |
| 11:50 am | Case Presentation |
| 12:00 noon | Panel Discussion / Q&A |
| 12:30 pm | Program Wrap-Up and Key Take-Away Points Tolga Erim, DO |
| 12:45 pm | Course Adjourns |